IL147992A0 - Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof - Google Patents
Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereofInfo
- Publication number
- IL147992A0 IL147992A0 IL14799201A IL14799201A IL147992A0 IL 147992 A0 IL147992 A0 IL 147992A0 IL 14799201 A IL14799201 A IL 14799201A IL 14799201 A IL14799201 A IL 14799201A IL 147992 A0 IL147992 A0 IL 147992A0
- Authority
- IL
- Israel
- Prior art keywords
- specificity
- necrosis factor
- tumor necrosis
- antibody molecules
- human tumor
- Prior art date
Links
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 title 1
- 102000057041 human TNF Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Compression Of Band Width Or Redundancy In Fax (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0013810.7A GB0013810D0 (en) | 2000-06-06 | 2000-06-06 | Biological products |
PCT/GB2001/002477 WO2001094585A1 (en) | 2000-06-06 | 2001-06-05 | Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IL147992A0 true IL147992A0 (en) | 2002-09-12 |
Family
ID=9893121
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14799201A IL147992A0 (en) | 2000-06-06 | 2001-06-05 | Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof |
IL147992A IL147992A (en) | 2000-06-06 | 2002-02-04 | Molecules of antibodies specific for human TNF, compounds and compositions containing them, a DNA sequence encoding a heavy and light chain of said antibody and processes for the production of said antibody |
IL195085A IL195085A0 (en) | 2000-06-06 | 2008-11-03 | Antibody molecules having specifity for human tnf ?? compounds and composition comprising them, dna sequence encoding heavy and light chain of said antibody and process for the production of said antibody |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL147992A IL147992A (en) | 2000-06-06 | 2002-02-04 | Molecules of antibodies specific for human TNF, compounds and compositions containing them, a DNA sequence encoding a heavy and light chain of said antibody and processes for the production of said antibody |
IL195085A IL195085A0 (en) | 2000-06-06 | 2008-11-03 | Antibody molecules having specifity for human tnf ?? compounds and composition comprising them, dna sequence encoding heavy and light chain of said antibody and process for the production of said antibody |
Country Status (43)
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
WO2004081026A2 (en) * | 2003-06-30 | 2004-09-23 | Domantis Limited | Polypeptides |
GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
EP1495056B1 (en) * | 2002-03-20 | 2011-03-02 | UCB Pharma, S.A. | Methods of analyzing antibody disulfide isomers |
US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
DK2371392T3 (en) | 2002-05-02 | 2015-08-31 | Wyeth Holdings Llc | Calicheamicin derivative / carrier conjugates |
ATE518885T1 (de) | 2002-05-28 | 2011-08-15 | Ucb Pharma Sa | Peg-positionsisomer von einem antikorper gegen tnfalpha (cdp870) |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
NZ598346A (en) * | 2002-07-19 | 2013-10-25 | Abbvie Biotechnology Ltd | Treatment of tnf alpha related disorders |
AU2003276844A1 (en) * | 2002-08-28 | 2004-03-19 | Pharmacia Corporation | Formulations of modified antibodies and methods of making the same |
WO2004019861A2 (en) * | 2002-08-28 | 2004-03-11 | Pharmacia Corporation | Stable ph optimized formulation of a modified antibody |
US20040105858A1 (en) * | 2002-08-29 | 2004-06-03 | Kim Joanne Young Hee Kwak | Diagnosis and treatment of infertility |
MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
WO2004039841A2 (en) | 2002-10-29 | 2004-05-13 | Borean Pharma A/S | Trimeric binding proteins for trimeric cytokines |
US7101978B2 (en) | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
WO2004065417A2 (en) * | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
GB0303337D0 (en) * | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
BRPI0407511A (pt) * | 2003-02-19 | 2006-02-14 | Pharmacia Corp | ésteres de polietilenoglicol ativados |
WO2004098578A2 (en) * | 2003-05-12 | 2004-11-18 | Altana Pharma Ag | Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517 |
WO2005014649A2 (en) * | 2003-08-08 | 2005-02-17 | Pharmacia Corporation | Method for the preparation of molecules having antibody activity |
DE602004004796T2 (de) * | 2003-08-13 | 2007-12-06 | Sandoz Ag | Expressionsvektoren, transformierte wirtszellen und fermentationsverfahren zur herstellung rekombinanter polypeptide |
ES2391457T3 (es) * | 2003-08-13 | 2012-11-26 | Sandoz Ag | Procedimiento para la purificación de polipéptidos recombinantes |
GB0319601D0 (en) * | 2003-08-20 | 2003-09-24 | Sandoz Ag | Production process |
KR100570422B1 (ko) * | 2003-10-16 | 2006-04-11 | 한미약품 주식회사 | 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법 |
CN100393748C (zh) * | 2003-11-06 | 2008-06-11 | 上海中信国健药业有限公司 | 全人源肿瘤坏死因子抗体,其制备方法以及药物组合物 |
KR100772800B1 (ko) * | 2003-11-17 | 2007-11-01 | 주식회사유한양행 | 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자 |
US7435799B2 (en) | 2004-01-08 | 2008-10-14 | Applied Molecular Evolution | TNF-α binding molecules |
CN100427504C (zh) * | 2004-06-02 | 2008-10-22 | 北京天广实生物技术有限公司 | TNFα高亲和力嵌合抗体及其用途 |
JP2008504356A (ja) * | 2004-06-30 | 2008-02-14 | ドマンティス リミテッド | 炎症性疾患を治療するための組成物及び方法 |
GB0425972D0 (en) * | 2004-11-25 | 2004-12-29 | Celltech R&D Ltd | Biological products |
US8022040B2 (en) * | 2004-11-29 | 2011-09-20 | The Regents Of The University Of California | Hydroxyapatite-binding peptides for bone growth and inhibition |
EP1831257B9 (en) * | 2004-12-29 | 2011-05-04 | Yuhan Corporation | Humanized antibody specific for tumor necrosis factor-alpha |
KR101465456B1 (ko) | 2005-05-16 | 2014-11-27 | 애브비 바이오테크놀로지 리미티드 | 미란성 다발관절염의 치료를 위한 tnf 억제제의 용도 |
AU2006254333B2 (en) * | 2005-06-01 | 2011-02-17 | Amgen Research (Munich) Gmbh | Anti-IL2 antibodies |
CA2609999C (en) | 2005-06-07 | 2017-05-30 | Esbatech Ag | Stable and soluble antibodies inhibiting tnf.alpha. |
GB0520169D0 (en) * | 2005-10-04 | 2005-11-09 | Celltech R&D Ltd | Biological products |
WO2007117685A2 (en) | 2006-04-07 | 2007-10-18 | Nektar Therapeutics Al, Corporation | Conjugates of an anti-tnf-alpha antibody |
EP2666472A3 (en) | 2006-04-10 | 2014-04-02 | Abbott Biotechnology Ltd | Uses and compositions for treatment of psoriatic arthritis |
US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
EP2010214A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
JP5385135B2 (ja) | 2006-07-03 | 2014-01-08 | チャールズ デイビッド アデア, | 細胞接着分子の発現を調節するための組成物 |
EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
AU2008223091B2 (en) * | 2007-03-02 | 2014-04-24 | Farnam Companies, Inc. | Sustained release pellets comprising wax-like material |
JP2010532749A (ja) * | 2007-06-07 | 2010-10-14 | サーモディクス ファーマシューティカルズ, インコーポレイテッド | 質量を削減した長時間作用剤形 |
EP2171451A4 (en) | 2007-06-11 | 2011-12-07 | Abbott Biotech Ltd | METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS |
EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
WO2015164330A1 (en) | 2014-04-21 | 2015-10-29 | Millennium Pharmaceuticals, Inc. | Anti-psyk antibody molecules and use of same for syk-targeted therapy |
EP2240515A1 (en) * | 2008-02-05 | 2010-10-20 | Delenex Therapeutics AG | Antigen-binding polypeptides against cartilage degeneration |
RU2532832C2 (ru) * | 2008-05-07 | 2014-11-10 | Аргос Терапьютикс, Инк. | Гуманизированные антитела против альфа-интерферона человека |
ES2890405T3 (es) | 2008-06-25 | 2022-01-19 | Novartis Ag | Humanización de anticuerpos de conejo usando un armazón de anticuerpo universal |
HUE032894T2 (hu) | 2008-06-25 | 2017-11-28 | Esbatech Alcon Biomed Res Unit | VEGF-gátló, stabilis és oldható antitestek |
US8293235B2 (en) | 2008-06-25 | 2012-10-23 | ESBATech, an Alcon Biomedical Research Unit, LLC | Humanization of rabbit antibodies using a universal antibody framework |
PT2307457T (pt) * | 2008-06-25 | 2018-10-16 | Esbatech Alcon Biomed Res Unit | Anticorpos estáveis e solúveis que inibem o tnf |
CN101684156B (zh) * | 2008-09-27 | 2011-12-28 | 苏州工业园区晨健抗体组药物开发有限公司 | 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用 |
US20110165063A1 (en) * | 2009-01-29 | 2011-07-07 | Abbott Laboratories | Il-1 binding proteins |
UA102722C2 (en) * | 2009-01-29 | 2013-08-12 | Эббви Инк. | Il-1 binding proteins |
ES2804450T3 (es) | 2009-07-10 | 2021-02-08 | Ablynx Nv | Método para la producción de dominios variables |
CA2774692C (en) | 2009-09-24 | 2017-12-19 | Ucb Pharma S.A. | Bacterial strain for recombinant protein expression, having protease deficient degp retaining chaperone activity, and knocked out tsp and ptr genes |
KR20170123723A (ko) | 2009-10-23 | 2017-11-08 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 항gcc 항체 분자와 관련 조성물 및 방법 |
GB201000591D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
GB201000590D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
GB201000588D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
GB201001791D0 (en) | 2010-02-03 | 2010-03-24 | Ucb Pharma Sa | Process for obtaining antibodies |
AU2011223547B2 (en) | 2010-03-04 | 2016-05-05 | Vet Therapeutics, Inc. | Monoclonal antibodies directed to CD52 |
US9616120B2 (en) | 2010-03-04 | 2017-04-11 | Vet Therapeutics, Inc. | Monoclonal antibodies directed to CD20 |
CN102958537B (zh) | 2010-04-07 | 2015-09-16 | Abbvie公司 | TNF-α结合蛋白 |
GB201012603D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Protein purification |
GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
GB201012784D0 (en) * | 2010-07-29 | 2010-09-15 | Ucb Pharma Sa | Method |
TWI538918B (zh) | 2010-10-20 | 2016-06-21 | 財團法人工業技術研究院 | 人源化之單株抗體、其核苷酸序列與其用途 |
UY33679A (es) | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
BR112013030824A8 (pt) | 2011-06-01 | 2018-04-03 | Actogenix Nv | Bactéria gram-positiva, ácido necleico recombinante, composição farmacêutica e vetor |
EP2546267A1 (en) | 2011-07-13 | 2013-01-16 | UCB Pharma S.A. | Bacterial host strain expressing recombinant DsbC |
LT2731973T (lt) | 2011-07-13 | 2018-02-26 | Ucb Biopharma Sprl | Bakterijų padermė, ekspresuojanti rekombinantinį dsbc |
JP6117212B2 (ja) | 2011-09-23 | 2017-04-19 | イントレクソン・アクトバイオテイクス・エヌブイIntrexon Actobiotics NV | 改変されたグラム陽性菌及びその使用 |
JP6329903B2 (ja) | 2011-09-23 | 2018-05-23 | イントレクソン・アクトバイオテイクス・エヌブイIntrexon Actobiotics NV | 改変されたグラム陽性菌及びその使用 |
EP2791171A1 (en) | 2011-12-16 | 2014-10-22 | Synthon Biopharmaceuticals B.V. | EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED |
US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
CA2880271C (en) | 2012-08-13 | 2021-10-19 | Genentech, Inc. | Anti-jagged anitbodies and methods of use |
US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
WO2016065042A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
KR102537099B1 (ko) | 2014-12-22 | 2023-05-25 | 유씨비 바이오파마 에스알엘 | 단백질 제조 방법 |
WO2017035430A2 (en) * | 2015-08-27 | 2017-03-02 | Kolltan Pharmaceuticals, Inc. | Anti-alk antibodies and methods for use thereof |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
CA3011331A1 (en) | 2016-01-14 | 2017-07-20 | Intrexon Actobiotics N.V. | Compositions and methods for the treatment of type 1 diabetes |
RU2680011C2 (ru) * | 2016-04-29 | 2019-02-14 | Закрытое Акционерное Общество "Биокад" | Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы |
EP3464318B1 (en) * | 2016-06-02 | 2021-04-21 | AbbVie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
AU2018374634A1 (en) | 2017-12-01 | 2020-05-28 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
WO2020157305A1 (en) | 2019-01-31 | 2020-08-06 | Numab Therapeutics AG | Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof |
KR102323342B1 (ko) * | 2019-04-26 | 2021-11-08 | 주식회사 와이바이오로직스 | IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체 |
CN111909268B (zh) * | 2019-05-07 | 2022-04-19 | 北京天成新脉生物技术有限公司 | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 |
TW202237638A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法 |
TW202237639A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 鳥苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法 |
IL305181A (en) | 2021-02-15 | 2023-10-01 | Takeda Pharmaceuticals Co | Cell therapy compositions and methods for modulating TGF-B signaling |
WO2023025248A1 (zh) | 2021-08-26 | 2023-03-02 | 映恩生物制药(苏州)有限公司 | 一种甾体化合物及其缀合物 |
SE545714C2 (en) * | 2021-09-24 | 2023-12-19 | Xbrane Biopharma Ab | Dna contructs for producing a pelb signal peptide |
SE545694C2 (en) * | 2021-09-24 | 2023-12-05 | Xbrane Biopharma Ab | Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides |
AU2022349814A1 (en) | 2021-09-24 | 2024-05-02 | Xbrane Biopharma Ab | Dna constructs and host cells for expressing recombinant protein |
WO2023154799A1 (en) | 2022-02-14 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination immunotherapy for treating cancer |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
US5030570A (en) | 1988-06-30 | 1991-07-09 | The Eunice Kennedy Shriver Center For Mental Retardation | DNA encoding and method of expressing human monoamine oxidase type A |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
PT92900A (pt) * | 1989-01-24 | 1990-07-31 | Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos | |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
NO309690B1 (no) | 1995-01-23 | 2001-03-12 | Western Atlas Int Inc | Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn |
AU2365795A (en) | 1995-04-20 | 1996-11-07 | Centocor Inc. | Multiple administrations of anti-tnf antibody |
MX336813B (es) | 1996-02-09 | 2016-02-02 | Abbvie Biotechnology Ltd | Anticuerpos humanos que ligan el tnfa humano. |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB9625640D0 (en) * | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
US6350860B1 (en) * | 1997-08-18 | 2002-02-26 | Innogenetics N.V. | Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders |
GB9720054D0 (en) * | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
ATE268609T1 (de) | 1998-03-12 | 2004-06-15 | Nektar Therapeutics Al Corp | Polyethylenglycolderivate mit benachbarten reaktiven gruppen |
GB9812545D0 (en) * | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
-
2000
- 2000-06-06 GB GBGB0013810.7A patent/GB0013810D0/en not_active Ceased
-
2001
- 2001-06-05 LT LTEP10010795.2T patent/LT2308975T/lt unknown
- 2001-06-05 RU RU2002105922/13A patent/RU2303604C2/ru active Protection Beyond IP Right Term
- 2001-06-05 MY MYPI20012634A patent/MY136603A/en unknown
- 2001-06-05 WO PCT/GB2001/002477 patent/WO2001094585A1/en active Application Filing
- 2001-06-05 ES ES01934209T patent/ES2337763T3/es not_active Expired - Lifetime
- 2001-06-05 DK DK09176251.8T patent/DK2230308T3/da active
- 2001-06-05 DE DE10192353T patent/DE10192353T1/de not_active Withdrawn
- 2001-06-05 DK DK16154916.7T patent/DK3059314T3/en active
- 2001-06-05 CZ CZ20020837A patent/CZ300737B6/cs unknown
- 2001-06-05 PL PL353960A patent/PL212738B1/pl unknown
- 2001-06-05 JP JP2002502126A patent/JP4064812B2/ja not_active Expired - Lifetime
- 2001-06-05 OA OA1200200368A patent/OA12282A/en unknown
- 2001-06-05 SK SK315-2002A patent/SK288343B6/sk not_active IP Right Cessation
- 2001-06-05 BR BRPI0106682A patent/BRPI0106682B8/pt not_active IP Right Cessation
- 2001-06-05 DE DE60140738T patent/DE60140738D1/de not_active Expired - Lifetime
- 2001-06-05 AP APAP/P/2002/002690A patent/AP2092A/en active
- 2001-06-05 TR TR2019/00227T patent/TR201900227T4/tr unknown
- 2001-06-05 DK DK10010795.2T patent/DK2308975T3/da active
- 2001-06-05 PT PT01934209T patent/PT1287140E/pt unknown
- 2001-06-05 HU HU0202346A patent/HU230561B1/hu active Protection Beyond IP Right Term
- 2001-06-05 PT PT91762518T patent/PT2230308E/pt unknown
- 2001-06-05 EP EP01934209A patent/EP1287140B1/en not_active Expired - Lifetime
- 2001-06-05 CN CNB018016294A patent/CN1289671C/zh not_active Expired - Lifetime
- 2001-06-05 CA CA2707766A patent/CA2707766C/en not_active Expired - Lifetime
- 2001-06-05 ES ES09176251T patent/ES2403217T3/es not_active Expired - Lifetime
- 2001-06-05 AU AU60511/01A patent/AU783756B2/en active Active
- 2001-06-05 EP EP16154916.7A patent/EP3059314B1/en not_active Expired - Lifetime
- 2001-06-05 IL IL14799201A patent/IL147992A0/xx unknown
- 2001-06-05 AT AT01934209T patent/ATE451460T1/de active
- 2001-06-05 MX MXPA01013440A patent/MXPA01013440A/es active IP Right Grant
- 2001-06-05 DK DK01934209.6T patent/DK1287140T3/da active
- 2001-06-05 PT PT16154916T patent/PT3059314T/pt unknown
- 2001-06-05 NZ NZ516596A patent/NZ516596A/en not_active IP Right Cessation
- 2001-06-05 PL PL399351A patent/PL218516B1/pl unknown
- 2001-06-05 BR BR0106682-0A patent/BR0106682A/pt not_active IP Right Cessation
- 2001-06-05 ES ES16154916T patent/ES2707714T3/es not_active Expired - Lifetime
- 2001-06-05 SI SI200131020T patent/SI2230308T1/sl unknown
- 2001-06-05 ES ES10010795.2T patent/ES2600080T3/es not_active Expired - Lifetime
- 2001-06-05 HU HU1600016A patent/HU230553B1/hu unknown
- 2001-06-05 SI SI200130960T patent/SI1287140T1/sl unknown
- 2001-06-05 EP EP10010795.2A patent/EP2308975B1/en not_active Expired - Lifetime
- 2001-06-05 HU HUP1600483A patent/HU230669B1/hu unknown
- 2001-06-05 DE DE122010000027C patent/DE122010000027I1/de active Pending
- 2001-06-05 CA CA2380298A patent/CA2380298C/en not_active Expired - Lifetime
- 2001-06-05 SI SI200131056A patent/SI2308975T1/sl unknown
- 2001-06-05 EP EP09176251A patent/EP2230308B1/en not_active Expired - Lifetime
- 2001-06-05 GB GB0128386A patent/GB2366800B/en not_active Expired - Lifetime
- 2001-06-05 ES ES200250012A patent/ES2230975B2/es not_active Expired - Lifetime
- 2001-06-05 KR KR1020027001131A patent/KR20020047097A/ko active Search and Examination
- 2001-06-05 PT PT100107952T patent/PT2308975T/pt unknown
- 2001-06-06 TW TW090113707A patent/TWI316088B/zh active
- 2001-06-06 PE PE2001000529A patent/PE20020292A1/es active IP Right Grant
- 2001-06-06 TW TW096150671A patent/TWI353358B/zh not_active IP Right Cessation
- 2001-06-06 AR ARP010102689A patent/AR033978A1/es active IP Right Grant
- 2001-06-06 US US09/875,221 patent/US7012135B2/en not_active Expired - Lifetime
- 2001-09-10 US US09/949,559 patent/US7186820B2/en not_active Expired - Lifetime
-
2002
- 2002-01-03 IS IS6217A patent/IS2808B/is unknown
- 2002-01-04 ZA ZA200200097A patent/ZA200200097B/xx unknown
- 2002-01-04 BG BG106278A patent/BG66072B1/bg unknown
- 2002-02-04 IL IL147992A patent/IL147992A/en active IP Right Grant
- 2002-02-04 NO NO20020554A patent/NO334808B1/no not_active IP Right Cessation
- 2002-02-06 EC EC2002004210A patent/ECSP024210A/es unknown
-
2003
- 2003-05-22 HK HK03103635.2A patent/HK1051385A1/xx not_active IP Right Cessation
-
2006
- 2006-03-13 US US11/374,231 patent/US7402662B2/en not_active Expired - Lifetime
- 2006-10-19 JP JP2006285205A patent/JP4476989B2/ja not_active Expired - Lifetime
-
2008
- 2008-06-18 US US12/141,667 patent/US7977464B2/en not_active Expired - Fee Related
- 2008-11-03 IL IL195085A patent/IL195085A0/en unknown
-
2009
- 2009-01-09 JP JP2009003953A patent/JP5185143B2/ja not_active Expired - Lifetime
-
2010
- 2010-03-09 CY CY20101100219T patent/CY1109889T1/el unknown
- 2010-03-15 FR FR10C0015C patent/FR10C0015I2/fr active Active
- 2010-03-29 LU LU91674C patent/LU91674I2/fr unknown
- 2010-04-13 BE BE2010C019C patent/BE2010C019I2/fr unknown
- 2010-05-13 CY CY2010011C patent/CY2010011I2/el unknown
-
2011
- 2011-03-22 HK HK11102887.9A patent/HK1148776A1/xx not_active IP Right Cessation
- 2011-11-18 IS IS8986A patent/IS3016B/is unknown
-
2013
- 2013-04-23 CY CY20131100333T patent/CY1114143T1/el unknown
- 2013-10-01 NO NO20131316A patent/NO339282B1/no not_active IP Right Cessation
-
2014
- 2014-10-23 NO NO2014026C patent/NO2014026I2/no unknown
-
2016
- 2016-04-26 NO NO20160694A patent/NO341218B1/no not_active IP Right Cessation
- 2016-11-10 CY CY20161101159T patent/CY1118220T1/el unknown
-
2017
- 2017-04-06 HU HUS1700013C patent/HUS1700013I1/hu unknown
-
2019
- 2019-01-24 CY CY20191100095T patent/CY1121173T1/el unknown
- 2019-04-19 CY CY2019018C patent/CY2019018I2/el unknown
- 2019-04-24 NL NL300982C patent/NL300982I9/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS1700013I1 (hu) | Humán tumor nekrózis faktor-alfa specifikus antitest molekulák és alkalmazásuk | |
EP2940044B8 (en) | Anti-tnf alpha antibodies for use in therapy | |
HUP0400284A3 (en) | Recombinant tumor specific antibody and use thereof | |
IL202332A0 (en) | Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer | |
GB0109537D0 (en) | Well treatment fluids and methods for the use thereof | |
HUP0300005A3 (en) | Modified cytokines for use in cancer therapy | |
AU2868601A (en) | Biaryl compounds, their preparation and their use in therapy | |
GB0115780D0 (en) | Therapeutic molecules and uses thereof | |
EP1437367A4 (en) | ANTIBODIES AND ITS USE | |
GB0022216D0 (en) | Human FAP-a-specific antibodies for use in cancer therapy | |
AUPQ884200A0 (en) | Novel therapeutic molecules and uses therefor - I | |
AUPR073300A0 (en) | Novel therapeutic molecules and uses therefor - V | |
AUPR073000A0 (en) | Novel therapeutic molecules and uses therefor - iv | |
AUPQ884400A0 (en) | Novel therapeutic molecules and uses therefor - II | |
AUPQ670400A0 (en) | Novel therapeutic molecules and uses therefor | |
AU2001228686A1 (en) | Biaryl compounds, their preparation and their use in therapy |